Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
2 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
22 Feb 24
424B7
Prospectus with selling stockholder info
10 Jan 24
D
$30.00 mm in equity, sold $30.00 mm, 1 investor
10 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
424B7
Prospectus with selling stockholder info
16 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
2 Nov 23
8-K
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
12 Oct 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
31 May 23
8-K
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
25 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
Regulation FD Disclosure
18 Apr 23
S-8
Registration of securities for employees
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
23 Feb 23
8-K
JPM Presentation January 2023
9 Jan 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
3 Nov 22
8-K
Relay Therapeutics Announces Proposed Public Offering of Common Stock
15 Sep 22
424B5
Prospectus supplement for primary offering
13 Sep 22
424B5
Prospectus supplement for primary offering
12 Sep 22
8-K
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
12 Sep 22
8-K
Regulation FD Disclosure
8 Sep 22
424B7
Prospectus with selling stockholder info
1 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
4 Aug 22
8-K
Departure of Directors or Certain Officers
27 Jul 22
Latest ownership filings
4
Peter Rahmer
29 Apr 24
4
Brian Adams
29 Apr 24
4
Thomas Catinazzo
29 Apr 24
4
Donald A Bergstrom
29 Apr 24
4
Thomas Catinazzo
29 Mar 24
4
Donald A Bergstrom
29 Mar 24
4
Peter Rahmer
29 Mar 24
4
Brian Adams
29 Mar 24
SC 13G/A
Casdin Capital, LLC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Peter Rahmer
31 Jan 24
4
Thomas Catinazzo
31 Jan 24
4
Donald A Bergstrom
31 Jan 24
4
Brian Adams
31 Jan 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Peter Rahmer
18 Jan 24
4
Sanjiv Patel
18 Jan 24
4
Thomas Catinazzo
18 Jan 24
4
Donald A Bergstrom
18 Jan 24
4
Brian Adams
18 Jan 24
4
Peter Rahmer
29 Dec 23
4
Thomas Catinazzo
29 Dec 23
4
Donald A Bergstrom
29 Dec 23
4
Brian Adams
29 Dec 23
4
Peter Rahmer
1 Nov 23
4
Thomas Catinazzo
1 Nov 23
4
Donald A Bergstrom
1 Nov 23
4
Brian Adams
1 Nov 23
SC 13G
Casdin Capital, LLC
2 Oct 23
4
Sanjiv Patel
29 Sep 23
4
Peter Rahmer
29 Sep 23
4
Thomas Catinazzo
29 Sep 23
4
Brian Adams
29 Sep 23
4
Donald A Bergstrom
29 Sep 23
4
Peter Rahmer
31 Jul 23
4
Thomas Catinazzo
31 Jul 23
4
Donald A Bergstrom
31 Jul 23
4
Brian Adams
31 Jul 23